Fueling Viking Therapeutics upside, analysts at Canaccord initiated coverage of the obesity treatment stock with a buy rating, and a price target of $106 a share With a short interest of 25%, Lemonade ...

Short interest is always a sign of how bearish investors may be on a stock. But it can also serve as a potential sign of a coming short squeeze, especially if the stock in question is rocketing higher ...

With 23% of its float short, Viking Therapeutics has been gaining momentum. In fact, since bottoming out at around $25, it’s now up to $38.88. With a short interest of 24.5%, Altimmune is another ...